PO.PS01.05 · 人群科学

Mapping the associations of 144 incidence risk factors with 39 cancers: An AI-driven systematic review and meta-analysis

海报缩略图:Mapping the associations of 144 incidence risk factors with 39 cancers: An AI-driven systematic review and meta-analysis
编号 2337 展板 3 时间 4/20 09:00–12:00 区域 Section 36 主讲 Shiyuan Tong
分会场 Epidemiology: Cancer Incidence, Mortality, Patterns, and Methodology
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Changfa Xia1, Shiyuan Tong2, Yongjie Xu1, Hui Yu2, Fang Liu2, Shiqing Chen2, Fei Zhao2, Junyi Ye2, Jing Liu2, Baoliang Zhu2, Xiaohui Wu2, Sibo Zhu2, Wanqing Chen3

1Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,2Shanghai Xiaohe Medical Laboratory Co. Ltd., Shanghai, China,3Office of Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

摘要 Abstract

Background: A comprehensive understanding of the associations between multiple risk factors and cancer incidence is crucial for evidence-based cancer control. While many studies have examined specific risk-cancer pairs, none have yet estimated the entire network of risks across cancer types. This study aims to quantity the associations between 144 cancer-related risk factors and the incidence of 39 cancer types. Methods: Using risk records from CanRisk-DB, a well-established repository that employs graph-based retrieval-augmented generation large language model agents within the PICOS-PRISMA framework, we synthesized relative risks (RRs) or hazard ratios (HRs) of cancer incidence from cohort studied between 1980 and 2024. We meta-analyzed the effect sizes using harmonized definitions and both graph-based and inverse variance approaches. The reliability of this artificial intelligence (AI)-driven meta-analysis was validated by comparing our estimated effects with those from published meta-analyses. Results: A total of 2,388 combinations between 144 risk factors and 39 cancer types were identified from CanRisk-DB. Among these, 131 and 120 risk factors were linked to 36 and 33 cancer types in females and males, respectively. Of 144 risk factors, 92.4% were modifiable. 67 factors were identified as causal risk factors only, such as family history of cancer, immunosuppressive agents, non-alcoholic fatty liver disease, and nitrogen dioxide pollution. However, 77 risk factors showed either causal and protective roles across cancer types, such as tobacco use, alcohol consumption, and type 2 diabetes. For instance, alcohol consumption was positively associated with several cancers (e.g., liver [RR = 1.46; 95% CI, 1.27-1.69], breast [RR = 1.09; 95% CI, 1.06-1.12], and colorectal [RR = 1.08; 95% CI, 1.02-1.13]) but inversely with kidney cancer (RR = 0.81; 95% CI, 0.76-0.87). The cancers with the greatest number of associated risk factors were lung (73 factors), colorectal (57), and liver (53). Overall, the majority of cancer types were associated with multiple modifiable risk factors: 34 cancers (87.2%) with at least 5 risks, 28 cancers (71.8%) with at least 10 risks, and 20 cancers (51.3%) with at least 15 risks. The effect sizes in our analysis are highly consistent with those reported in published meta-analyses (Spearman's ρ = 0.93). Conclusion: AI-driven systematic reviews and meta-analyses accurately captured the complex network of associations between cancers and risk factors. Mapping these relationships facilitated a better understanding of the attributable risk of cancer, thereby informing strategies for cancer prevention and control.
利益披露 Disclosure
C. Xia, None. S. Tong, Shanghai Xiaohe Medical Laboratory Co. Ltd., Shanghai, China Employment. Y. Xu, None. H. Yu, Shanghai Xiaohe Medical Laboratory Co. Ltd., Shanghai, China Employment. F. Liu, Shanghai Xiaohe Medical Laboratory Co. Ltd., Shanghai, China Employment. S. Chen, Shanghai Xiaohe Medical Laboratory Co. Ltd., Shanghai, China Employment. F. Zhao, Shanghai Xiaohe Medical Laboratory Co. Ltd., Shanghai, China Employment. J. Ye, Shanghai Xiaohe Medical Laboratory Co. Ltd., Shanghai, China Employment. J. Liu, Shanghai Xiaohe Medical Laboratory Co. Ltd., Shanghai, China Employment. B. Zhu, Shanghai Xiaohe Medical Laboratory Co. Ltd., Shanghai, China Employment. X. Wu, Shanghai Xiaohe Medical Laboratory Co. Ltd., Shanghai, China Employment. S. Zhu, Shanghai Xiaohe Medical Laboratory Co. Ltd., Shanghai, China Employment. W. Chen, None.

在会议检索中打开